Abstract: The invention relates to antimicrobial and/or antiviral fabric compositions comprising ascorbic acid, citric acid, sodium hypophosphite, or a mixture thereof. The ascorbic acid may be covalently attached to at least one cellulosic portion of the fabric composition. The invention also relates to methods for preparing such fabric compositions.

Abstract: The invention relates to fabric compositions with improved hemostatic properties comprising attached a zeolite, a zeolite/pectin complex, or a mixture thereof, and methods of preparing such fabric compositions.

Abstract: Single layered nonwoven wound dressings containing (1) about 5% by weight to about 95% by weight (e.g., 5% to 95%) non-scoured, non-bleached greige cotton fibers, (2) about 5% by weight to about 95% by weight (e.g., 5% to 95%) bleached cotton fibers, and (3) about 5% by weight to about 60% by weight (e.g., 5% to 60%) hydrophobic fibers (e.g., polypropylene, nylon); all percentages adding up to 100 wt %. Also, multi-layered nonwoven wound dressings, containing (1) at least one inner layer containing (a) about 50% by weight to about 95% by weight (e.g., 50% to 95) non-scoured, non-bleached greige cotton fibers and (b) about 5% by weight to about 50% by weight (e.g., 5% to 50%) hydrophobic fibers, all percentages adding up to 100 wt %, and (2) at least one outer layer containing (a) about 5% by weight to about 95% by weight (e.g., 5% to 95%) non-scoured, non-bleached greige cotton fibers, (b) about 5% by weight to about 95% by weight (e.g.

Abstract: Single layered nonwoven wound dressings containing (1) about 5% by weight to about 95% by weight (e.g., 5% to 95%) non-scoured, non-bleached greige cotton fibers, (2) about 5% by weight to about 95% by weight (e.g., 5% to 95%) bleached cotton fibers, and (3) about 5% by weight to about 60% by weight (e.g., 5% to 60%) hydrophobic fibers (e.g., polypropylene, nylon); all percentages adding up to 100 wt %. Also, multi-layered nonwoven wound dressings, containing (1) at least one inner layer containing (a) about 50% by weight to about 95% by weight (e.g., 50% to 95) non-scoured, non-bleached greige cotton fibers and (b) about 5% by weight to about 50% by weight (e.g., 5% to 50%) hydrophobic fibers, all percentages adding up to 100 wt %, and (2) at least one outer layer containing (a) about 5% by weight to about 95% by weight (e.g., 5% to 95%) non-scoured, non-bleached greige cotton fibers, (b) about 5% by weight to about 95% by weight (e.g.

Abstract: A wound dressing containing cellulose-containing material and alginate, wherein the alginate is crosslinked through a polycarboxylic acid ester bond to the celluose of the cellulose-containing material. A method for preparing a wound dressing is disclosed wherein alginate is crosslinked to cellulose through a polycarboxylic acid ester bond, comprising introducing cellulose-containing material into an aqueous solution wherein the aqueous solution contains water, alginate, a crosslinker, optionally an acid catalyst, and optionally polyethylene glycol to form cellulose-containing material wherein alginate is crosslinked to cellulose through a polycarboxylic acid ester bond, drying, and curing. A wound dressing wherein the wound dressing is prepared by the above method.

Abstract: A wound dressing containing cellulose-containing material and alginate, wherein the alginate is crosslinked through a polycarboxylic acid ester bond to the celluose of the cellulose-containing material.

Abstract: Agonists and Antagonist of bombesin are derivatives of naturally occurring bombesin possessing a methyl sulfide or a methyl amide bond connecting the two amino acids on the carboxy terminal end. Agonist and antagonist activities are confirmed using conventional competitive binding and biochemical assays as well as conventional physiological tests and the use of these derivatives in a variety of conditions. Use of these peptides include stimulating or antagonizing growth of tissues, especially lung, and a means for effecting treatment for digestional disorders. Treatment comprises administering to a patient in need thereof, an effective amount of a bombesin analog.

Abstract: Disclosed are Agonists and Antagonists of bombesin which are derivatives of naturally occurring bombesin possessing modified derivatives of phenylalanine. Agonist and antagonist activities are confirmed using conventional competitive binding and biochemical assays as well as conventional physiological tests and the use of these derivatives in a variety of conditions.Use of these peptides may be useful for stimulating or antagonising growth of tissues, especially lung, and of digestion. Treatment comprises administering to a patient in need thereof, an effective amount of a bombesin analog.

Abstract: The following novel oligopeptide compounds which possess phytotoxic and plant growth regulating properties and methods for their use are disclosed: R.sub.1 -N(R.sub.2)-D,L-Ala-D,L-Leu-N(R.sub.2).DELTA.Phe-Gly-OR.sub.3 ; in which R.sub.1 is H or a protecting group at the amino terminus of the type 9-fluorenylmethoxycarbonyl, or benzyloxycarbonyl, R.sub.2 is an alkyl of 2 to 3 carbon atoms, R.sub.3 is hydrogen or an alkyl of 2 to 3 carbon atoms, and .DELTA.Phe is dehydrophenylalanine. R.sub.1 -D,L-Leu-N(R.sub.4)-.DELTA.Phe-Gly-OR.sub.3 ; R.sub.1 Aib-N(R.sub.2)-.DELTA.Phe-Gly-OR.sub.3 ; R.sub.1 -Ala-N(R.sub.5)-.DELTA.Phe-Gly-OR.sub.3 ; R.sub.1 -Val-N(R.sub.2)-.DELTA.Phe-Gly-OR.sub.3 ; wherein R.sub.1 is H or a protecting group at the amino terminus of the type tert-butyloxycarbonyl-(BOC), 9-fluorenylmethyloxycarbonyl, or benzyloxycarbonyl, R.sub.2 is an alkyl of 1 to 3 carbon atoms, R.sub.3 is hydrogen or an alkyl of 1 to 3 carbon atoms, and .DELTA.Phe is dehydrophenylalanine.